Overview
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
Status:
Completed
Completed
Trial end date:
2006-12-01
2006-12-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion Criteria:- Surgical diagnosis of endometriosis within the last 10 years
- Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual
cycles who are willing to use non-hormonal contraception
Exclusion Criteria:
- Conditions requiring the use of chronic pain therapy
- Prophylactic use of analgesics to avoid endometriosis-related pain